Obesity Drug Access and Clinical Advances

GLP-1 access is expanding through Medicare, retail delivery, and new formulations, while Medicaid and employer coverage remain uncertain. Lilly’s Mochi litigation continues over allegations involving corporate practice of medicine and prescribing/dispensing arrangements; preliminary animal combination data and a company-reported CRB-913 Phase 1b result add signals requiring fuller, longer-term, and independent evidence.